Bangkas, Maria Perpetua Julianne FEU-NRMF

BSN 4E1

Room 312

GENERIC BRAND CLASSIFICAT DOSAGE INDICATION CONTRAINDICATI ADVERSE NURSING

NAME NAME ION ON EFFECTS RESPONSIBILI
TIES
-Ofloxacin -Antibacterial -indicated for -contraindicated -Liver -Determine
(Bactericidal; the for the treatment damage and history of
ofloxacin treatment of of certain dysglycemia hypersensitivi
acts adults with sexually ty reactions
intracellularl mild to transmitted -multiple to drug.
y by moderate diseases adverse
inhibiting infections events as -history of
DNA gyrase. (unless -hypersensitivity "fluoroquinol allergies,
DNA gyrase otherwise to ofloxacin or one particularly to
is an indicated) other quinolone toxicity". drugs, before
essential caused by drugs. therapy is
bacterial susceptible -Reports of initiated.
enzyme that strains of -patients with hepatic or
is a critical microorganis liver disease hypersensiti -Monitor for
catalyst in ms. vity manifestation
the -contraindicated vasculitis s of
replication, within the hypersensitivi
transcription, pediatric -increased ty.
deactivation, population, risk of
and repair of pregnancy, tendinopath
bacterial nursing mothers, y (including
DNA.) patients with rupture)
psychiatric
illnesses and in -
patients with Hematologic
epilepsy or other reactions
seizure (including
disorders. agranulocyt
osis,
thrombocyto
penia), and
renal
toxicities
GENERIC BRAND CLASSIFICAT DOSAGE INDICATION CONTRAINDICATI ADVERSE NURSING
NAME NAME ION ON EFFECTS RESPONSIBILI
TIES
- -Antibacterial -indicated for -Penicillin or -GI -Determine
Cefuroxime (Bactericidal; the other allergy. disturbances history of
ofloxacin treatment of -History of colitis , transient hypersensitivi
acts adults with -Renal increase of ty reactions
intracellularl mild to impairment AST, ALT, to drug.
y by moderate LDH,
inhibiting infections eosinophilia, -history of
DNA gyrase. (unless bitter taste; allergies,
DNA gyrase otherwise convulsions particularly to
is an indicated) (overdose) drugs, before
essential caused by therapy is
bacterial susceptible -Large doses initiated.
enzyme that strains of can cause
is a critical microorganis cerebral -Monitor for
catalyst in ms. irritation manifestation
the and s of
replication, convulsions; hypersensitivi
transcription, nausea, ty.
deactivation, vomiting, -Lab tests:
and repair of diarrhoea, Perform
bacterial erythema culture and
DNA.) multiforme, sensitivity
Stevens- tests before
Johnson initiation of
syndrome, therapy and
epidermal periodically
necrolysis. during
- therapy if
Potentially indicated.
Fatal: Therapy may
Anaphylaxis, be instituted
nephrotoxici pending test
ty, results.
pseudomem Monitor
branous periodically
colitis. BUN and
 creatinine
clearance.

Bangkas, Maria Perpetua Julianne FEU-NRMF BSN 4E1 NCP-room

312

ASSESSMENT NURSING NURSING PLANNING INTERVENTIO RATIONALES EVALUATIONS

DIAGNOSIS ANALYSIS NS
SUBJECTIVE: -acute pain -unpleasant -after 30 -assess and - to establish -after 30
related to sensory and minutes of interview rapport minutes of
“maayos appearance of emotional nursing client (nurse nursing
naman ang epigastric pain experience intervention patient interventions
pakiramdam as manifested arising from the patients intercation) done to
ko. pero may -to visualize
by actual or pain will be payient was
nararamdama -assess pain degree of
verbalization potential reduced to a able to
n akong sakit (location, discomfort
of the client tissue tolerable level manifest the
paminsan and positive damage. as manifested duration, following:
minsan” as facial grimace. by: intensity)
verbalized by -to have -painscale
the patient. -painscale -attain rating changed
baseline data
rating from 6 patients vital from 6 to 3
OBJECTIVE: to 2 signs -promotes
relaxation and -positive
-facial grimace -deceased -provide verbalization
diverts
facial patient some of pain has
-pain scale of sensation of
grimicing diversional decreased and
6 pain
activities facial grimce
-clients -pain is has lessened.
MEASURES:
verbalization subjective and
BP- 130/70 of pain level cannot be felt
-accept and
has by others
acknowledge
TEMP-37.6 decreased.
the pain
RR-19 experience of
patient - to promote
PR-87 non
-provide
pharmacologic
comfort
al pain
measures
management